Striving towards access to essential medicines for human and animal health; a situational analysis of access to and use of antifungal medications for histoplasmosis in Ethiopia.
Authors: Robertson Eleanor, Abera Cherinet, Wood Kelly, Deressa Kabeba, Mesfin Samuel, Scantlebury Claire
Journal: PloS one
Summary
# Editorial Summary: Antifungal Access for Histoplasmosis in Ethiopia — A One-Health Perspective Histoplasmosis represents a substantial but largely invisible disease burden in Ethiopia, with approximately one in five horses harbouring the infection alongside an unmeasured human disease prevalence; yet antifungal medications remain critically scarce for treating both equine and human cases. Robertson and colleagues conducted qualitative research across six regions of Oromia in late 2018, interviewing 27 healthcare and veterinary professionals (including doctors, pharmacists, veterinarians and para-veterinarians) and facilitating 11 focus groups with equid owners, veterinarians and pharmacists to explore systemic barriers to antifungal access using thematic analysis. Two dominant constraint categories emerged: structural factors including Ethiopia's dependency on medicine importation, poor pharmaceutical supply-chain data collection, inadequate diagnostic capacity for fungal disease, and healthcare systems requiring significant out-of-pocket payments; alongside human factors such as cost perception relative to competing household priorities, cultural stigma delaying treatment-seeking behaviour, and widespread reliance on unproven home remedies that undermine trust in formal healthcare. For equine professionals in Ethiopia and similar resource-constrained settings, this research underscores that improving histoplasmosis outcomes requires multi-sectoral intervention beyond clinical capacity alone—addressing supply-chain transparency, diagnostic infrastructure, and community health literacy will be as critical as antifungal availability itself.
Read the full abstract on PubMed
Practical Takeaways
- •In resource-limited settings like Ethiopia, histoplasmosis in equids is highly prevalent (20% infection rate) but severely undertreated due to systemic supply issues—awareness of local disease burden is essential for practitioners
- •Improving antifungal access requires addressing not just procurement but also community education to counter stigma, reduce reliance on ineffective home remedies, and build trust in veterinary treatments
- •Equine practitioners should advocate for policy review of pharmaceutical supply chains and cross-sectorial (human and animal health) collaboration, as equid disease control directly impacts public health in endemic areas
Key Findings
- •One in five horses in Ethiopia are estimated to be infected with histoplasmosis, representing a major equine welfare and socio-economic concern
- •Structural barriers to antifungal access include national reliance on importation, poor demand forecasting, weak diagnostic capacity, and healthcare systems dependent on out-of-pocket expenditure
- •Human factors limiting treatment include cost perception relative to competing needs, social stigma delaying treatment-seeking, and preference for home remedies over pharmaceutical options
- •Supply chain inefficiencies and lack of trust in healthcare/veterinary provisions due to perceived medication inefficacy are critical gaps requiring cross-sectorial intervention